Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mindray’s Higher 2008 Results Fail to Impress Investors

publication date: Mar 5, 2009

Mindray Medical (迈瑞医疗国际有限公司), the Shenzhen-based medical device maker, reported positive results for its Q4 and full-year 2008. Revenues climbed to $547.4 million, which represented a 61% increase in China and a 110% improvement in international markets. Non-GAAP income rose 50% to $132.7 million. Although Mindray’s numbers were healthy, investors seemed unhappy that the company’s overall business did not grow more rapidly. More details...

Stock Symbol: (NYSE: MR) (NSDQ: DSCP)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital